Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study - Takeaways - MDSpire

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study

  • By

  • Emma Birnie

  • Magda Vergouwe

  • Brent Appelman

  • Jason J Biemond

  • Jarom Heijmans

  • Brooke E Nichols

  • W Joost Wiersinga

  • Stephanie Popping

  • on behalf of

  • the TURN-COVID studygroup

  • Matthijs R A Welkers

  • Hans L Zaaijer

  • Frans J van Ittersum

  • Maarten F Schim van der Loeff

  • Marije K Bomers

  • Marie José Kersten

  • Mette D Hazenberg

  • Marc van der Valk

  • E Marleen Kemper

  • Frits R Rosendaal

  • Mark G J de Boer

  • Renée A Douma

  • Marcel van den Berge

  • Robert-Jan Hassing

  • Heidi S M Amerlaan

  • Marit G A van Vonderen

  • Janneke E Stalenhoef

  • Robin Soetekouw

  • Frank van de Veerdonk

  • Marvin A H Berrevoets

  • Robbert J van Alphen

  • Frits van Osch

  • Jiri F P Wagenaar

  • Rob J van Marum

  • Astrid M L Oude Lashof

  • Cees van Nieuwkoop

  • Eliane M S Leyten

  • Hazra S Moeniralam

  • Joost N Vermeulen

  • March 26, 2025

  • 0 min

Share

  • 1

    Nirmatrelvir/ritonavir is priced at approximately $1375 in the Netherlands and is used for high-risk COVID-19 patients to prevent severe disease.

  • 2

    The study evaluated health outcomes and cost-effectiveness using a decision-analytic model with data from 949 high-risk individuals infected with SARS-CoV-2.

  • 3

    Nirmatrelvir/r could reduce hospitalizations and deaths by 21% to 89% and is cost-effective at prices below $512 with low effectiveness and $1071 with high effectiveness.

  • 4

    Current low baseline event rates for hospitalization suggest nirmatrelvir/r can reduce severe outcomes cost-effectively if drug prices are reduced by 22% to 63%.

  • 5

    The findings emphasize the need for policy makers to reevaluate current drug pricing to enhance the uptake of nirmatrelvir/r among high-risk COVID-19 patients.

Original Source(s)

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study

  • by Emma Birnie, Magda Vergouwe, Brent Appelman, Jason J Biemond, Jarom Heijmans, Brooke E Nichols, W Joost Wiersinga, Stephanie Popping, on behalf of, the TURN-COVID studygroup, Matthijs R A Welkers, Hans L Zaaijer, Frans J van Ittersum, Maarten F Schim van der Loeff, Marije K Bomers, Marie José Kersten, Mette D Hazenberg, Marc van der Valk, E Marleen Kemper, Frits R Rosendaal, Mark G J de Boer, Renée A Douma, Marcel van den Berge, Robert-Jan Hassing, Heidi S M Amerlaan, Marit G A van Vonderen, Janneke E Stalenhoef, Robin Soetekouw, Frank van de Veerdonk, Marvin A H Berrevoets, Robbert J van Alphen, Frits van Osch, Jiri F P Wagenaar, Rob J van Marum, Astrid M L Oude Lashof, Cees van Nieuwkoop, Eliane M S Leyten, Hazra S Moeniralam, Joost N Vermeulen

  • March 26, 2025

Related Content

Long-term epidemiological patterns of pediatric infectious diseases in an urban district of Shanghai, 2015–2023

Cough Audio Recognition for Early Detection of Respiratory Diseases: Algorithm Development and Validation Study

The CRISPR-powered Diagnostic SLEUTH

Novel DNA-guided system may support future RNA diagnostics and mutation detection

  • May 22, 2026

  • 2 min